As of 2025-04-23, the Relative Valuation of Vaxcyte Inc (PCVX) is (121.06) USD. This relative valuation is based on P/E multiples. With the latest stock price at 31.26 USD, the upside of Vaxcyte Inc based on Relative Valuation is -487.3%.
The range of the Relative Valuation is (100.02) - (121.35) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 27.8x - 41.4x | 36.6x |
| Forward P/E multiples | 23.8x - 33.7x | 30.6x |
| Fair Price | (100.02) - (121.35) | (121.06) |
| Upside | -420.0% - -488.2% | -487.3% |
| Date | P/E |
| 2025-04-23 | -9.35 |
| 2025-04-22 | -8.68 |
| 2025-04-21 | -8.43 |
| 2025-04-17 | -8.51 |
| 2025-04-16 | -8.08 |
| 2025-04-15 | -8.39 |
| 2025-04-14 | -8.89 |
| 2025-04-11 | -8.66 |
| 2025-04-10 | -7.78 |
| 2025-04-09 | -8.55 |
| 2025-04-08 | -8.38 |
| 2025-04-07 | -9.02 |
| 2025-04-04 | -8.77 |
| 2025-04-03 | -8.48 |
| 2025-04-02 | -9.35 |
| 2025-04-01 | -8.95 |
| 2025-03-31 | -10.48 |
| 2025-03-28 | -19.28 |
| 2025-03-27 | -19.64 |
| 2025-03-26 | -19.03 |
| 2025-03-25 | -19.96 |
| 2025-03-24 | -20.49 |
| 2025-03-21 | -20.72 |
| 2025-03-20 | -20.67 |
| 2025-03-19 | -21.13 |
| 2025-03-18 | -20.74 |
| 2025-03-17 | -20.88 |
| 2025-03-14 | -20.64 |
| 2025-03-13 | -20.27 |
| 2025-03-12 | -20.33 |
| 2025-03-11 | -19.39 |
| 2025-03-10 | -19.12 |
| 2025-03-07 | -19.76 |
| 2025-03-06 | -20.76 |
| 2025-03-05 | -20.51 |
| 2025-03-04 | -19.49 |
| 2025-03-03 | -20.01 |
| 2025-02-28 | -20.27 |
| 2025-02-27 | -20.60 |
| 2025-02-26 | -21.83 |
| 2025-02-25 | -22.02 |
| 2025-02-24 | -22.67 |
| 2025-02-21 | -22.13 |
| 2025-02-20 | -22.89 |
| 2025-02-19 | -23.14 |
| 2025-02-18 | -22.89 |
| 2025-02-14 | -23.31 |
| 2025-02-13 | -23.27 |
| 2025-02-12 | -23.71 |
| 2025-02-11 | -23.63 |